Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 01 July 2016 | By Zachary Brennan
In what might turn out to be an odd mistake, the current US Food and Drug Administration (FDA) Commissioner Rob Califf was included in a database of pharmaceutical company payments to physicians updated by the US Centers for Medicare & Medicaid Services (CMS) on Thursday.
The database says Califf received five payments from GlaxoSmithKline for travel, lodging, food and beverages, as well as a more than $5,000 consulting fee from AstraZeneca in 2015. In 2014, when he was not working for FDA, Califf received almost $32,000 from companies and in 2013, he received more than $28,000.
An FDA spokesperson told Focus: “We can’t immediately confirm the accuracy of data that dates back to 2015, but Commissioner Califf wasn’t on travel or at such an event on that date. Throughout his government service, he has strictly adhered to federal ethics requirements and has no financial ties to industry. We are examining whether the entry was made in error.”
An FDA spokesperson later told Focus: "Commissioner Califf has filed a dispute with CMS in regard to the reported data. Throughout his government service, he has strictly adhered to federal ethics requirements and has no financial ties to industry. We look forward to the data being corrected."
As The New York Times reported in September 2015, ahead of his confirmation as commissioner, Califf has received about $215,000 in consulting fees from 2009 to early 2015, though as many physicians note, academic doctors are often paid consulting fees as their universities conduct clinical research.
And though Califf is the only FDA leader listed (that Focus could find), former commissioner under President George H. W. Bush, David Kessler, received $40,000 from Immucor, while FDA’s commissioner under George W. Bush, Andrew Von Eschenbach, received more than $50,000 from Chugai Pharmaceutical Co., Eli Lilly and E.R. Squibb and Sons.
FDA’s former deputy commissioner for medical and scientific affairs Scott Gottlieb, a resident fellow at the American Enterprise Institute, also was included in the database and pulled in $199,951 in 2015, including more than $60,000 from GlaxoSmithKline, more than $50,000 from Daiichi Sankyo and more than $65,000 from Vertex Pharmaceuticals. Gottlieb told Focus that he sits on the GSK research and development board, serves on the board of directors for Daiichi and acts as a senior adviser to Vertex.
Editor's Note: This article was updated on 7/5/16 with the latest quote from FDA's spokesman saying Califf has filed a dispute with CMS over the funds listed in the database for 2015.
Tags: Robert Califf, FDA commissioner, industry payments to FDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.